HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Influence of heme-based solutions on stress protein expression and organ failure after hemorrhagic shock.

AbstractOBJECTIVE:
Hemoglobin-based oxygen carriers (e.g., diaspirin-cross-linked hemoglobin [DCLHb] and hemoglobin glutamer-200 [HbG]) may have potential in the treatment of hemorrhagic shock. The nitric oxide scavenging and direct vasoconstrictive side effects of free hemoglobin of currently available preparations may increase organ injury after shock in contrast to non-oxygen-carrying heme solutions (e.g., hemin arginate [HAR]). However, both classes of substances might induce the protective enzyme heme oxygenase (HO)-1, particularly in the liver. The aim of the study was to assess the role of pretreatment with DCLHb, HbG, or HAR on HO-1 expression and organ injury after hemorrhagic shock.
DESIGN:
Prospective controlled laboratory study.
SETTING:
Animal research laboratory at a university hospital.
SUBJECTS:
Male Sprague-Dawley rats (200-300 g body weight, n = 5-12/group).
INTERVENTIONS:
Twenty-four hours after different doses of DCLHb, HbG (each 1, 2, or 3 g/kg of body weight), or HAR (5, 25, or 75 mg/kg of body weight), the protein expression of HO-1 and heat shock protein-70 in liver, kidney, heart, lungs, and aorta was determined. Twenty-four hours after pretreatment with DCLHb, HbG, or HAR, rats were subjected to hemorrhage (mean arterial blood pressure, 35-40 mm Hg for 1 or 2 hrs)/resuscitation (5 or 4 hrs, respectively). Animals treated with Ringer's solution (30 mL/kg of body weight) served as controls. In additional experiments, HO activity was blocked with tin mesoporphyrin-IX.
MEASUREMENTS AND MAIN RESULTS:
DCLHb, HbG, and HAR dose-dependently induced HO-1 protein but not heat shock protein-70. Pretreatment with DCLHb or HbG shortened the onset of decompensation in shock (DCLHb, 40 +/- 11 mins; HbG, 36 +/- 4 mins) compared with vehicle (68 +/- 4 mins, p < .05) and HAR pretreatment (81 +/- 7 mins, p < .05). High doses of DCLHb pretreatment increased mortality (2 hrs of shock, 80%; p < .05 vs. vehicle or HAR). Pretreatment with HAR led to higher shed blood volumes (p < .05) and higher hepatocellular ATP levels (2 hrs of shock, p < .05 vs. DCLHb and HbG). Blockade of HO activity by tin mesoporphyrin-IX abolished the protection mediated by HAR.
CONCLUSIONS:
Although DCLHb, HbG, and HAR induce HO-1 in the absence of an unspecific stress response, only HAR pretreatment protects against shock-induced organ failure. Although the underlying mechanisms of positive HAR priming are not completely understood, the induction of HO-1 expression and the lack of nitric oxide scavenging through HAR may play an important role.
AuthorsDarius Kubulus, Hauke Rensing, Markus Paxian, Jan-Tobias Thierbach, Tanja Meisel, Heinz Redl, Michael Bauer, Inge Bauer
JournalCritical care medicine (Crit Care Med) Vol. 33 Issue 3 Pg. 629-37 (Mar 2005) ISSN: 0090-3493 [Print] United States
PMID15753757 (Publication Type: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Blood Substitutes
  • HSP70 Heat-Shock Proteins
  • Hemoglobins
  • hemoglobin glutamer-200
  • Hemin
  • Heme Oxygenase (Decyclizing)
  • Heme Oxygenase-1
  • diaspirin-cross-linked hemoglobin
  • Aspirin
Topics
  • Animals
  • Aspirin (analogs & derivatives, pharmacology, therapeutic use)
  • Blood Substitutes (pharmacology, therapeutic use)
  • Dose-Response Relationship, Drug
  • HSP70 Heat-Shock Proteins (drug effects, metabolism)
  • Heme Oxygenase (Decyclizing) (drug effects, metabolism)
  • Heme Oxygenase-1
  • Hemin (analogs & derivatives, pharmacology, therapeutic use)
  • Hemoglobins (pharmacology, therapeutic use)
  • Liver (drug effects, metabolism)
  • Liver Failure (physiopathology)
  • Male
  • Prospective Studies
  • Rats
  • Rats, Sprague-Dawley
  • Shock, Hemorrhagic (drug therapy, mortality)
  • Survival Analysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: